Hu Li, Ph.D.
and his research team are focused on systems biology, systems pharmacology and individualized systems
medicine. Li's team is active in developing novel network tools and
harnessing machine learning methods to study context-dependent
activities of regulatory networks at genome-wide scale. The major
theme in the research team is to develop novel computational methods
that can detect meaningful biological information embedded in the sea
of Big Data and uncover novel regulatory mechanisms that explain the
properties of biological phenotypes to benefit individualized disease
diagnosis, drug discovery, and precision medicine. The developed
computational platforms can greatly illuminate the understanding of
disease mechanisms underlying drugs' modes of action, addressing key
challenges in Big Data-oriented biomedical complex systems and will
ultimately lead to precision medicine for each patient suffering from
a devastating disease. His team is currently working on ways to
elucidate how regulatory networks that constitute a constellation of
genes drive disease formation and progression in different individual
patients to provide novel perspective in designing network-based
treatments to realize translational individualized precision medicine.